253 related articles for article (PubMed ID: 23801634)
1. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.
Krejsgaard T; Litvinov IV; Wang Y; Xia L; Willerslev-Olsen A; Koralov SB; Kopp KL; Bonefeld CM; Wasik MA; Geisler C; Woetmann A; Zhou Y; Sasseville D; Odum N
Blood; 2013 Aug; 122(6):943-50. PubMed ID: 23801634
[TBL] [Abstract][Full Text] [Related]
2. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).
Willerslev-Olsen A; Litvinov IV; Fredholm SM; Petersen DL; Sibbesen NA; Gniadecki R; Zhang Q; Bonefeld CM; Wasik MA; Geisler C; Zhou Y; Woetmann A; Sasseville D; Krejsgaard T; Odum N
Cell Cycle; 2014; 13(8):1306-12. PubMed ID: 24621498
[TBL] [Abstract][Full Text] [Related]
3. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
4. Protein and mRNA Expression Levels of Interleukin-17A, -17F and -22 in Blood and Skin Samples of Patients with Mycosis Fungoides.
Papathemeli D; Patsatsi A; Papanastassiou D; Koletsa T; Papathemelis T; Avgeros C; Pikou O; Lazaridou E; Georgiou E
Acta Derm Venereol; 2020 Nov; 100(18):adv00326. PubMed ID: 33170303
[TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy promotes HIF-1α-mediated glycolysis and IL-17F pathways in cutaneous T-cell lymphoma.
Wang B; Li K; Wang H; Shen X; Zheng J
Exp Dermatol; 2020 Oct; 29(10):987-992. PubMed ID: 32573814
[TBL] [Abstract][Full Text] [Related]
6. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway.
Krejsgaard T; Ralfkiaer U; Clasen-Linde E; Eriksen KW; Kopp KL; Bonefeld CM; Geisler C; Dabelsteen S; Wasik MA; Ralfkiaer E; Woetmann A; Odum N
J Invest Dermatol; 2011 Jun; 131(6):1331-8. PubMed ID: 21346774
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3.
Nielsen M; Nissen MH; Gerwien J; Zocca MB; Rasmussen HM; Nakajima K; Röpke C; Geisler C; Kaltoft K; Ødum N
Blood; 2002 Feb; 99(3):973-7. PubMed ID: 11807001
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
[TBL] [Abstract][Full Text] [Related]
9. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
10. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.
Willerslev-Olsen A; Krejsgaard T; Lindahl LM; Litvinov IV; Fredholm S; Petersen DL; Nastasi C; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Kilian M; Koralov SB; Odum N
Blood; 2016 Mar; 127(10):1287-96. PubMed ID: 26738536
[TBL] [Abstract][Full Text] [Related]
11. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.
McGirt LY; Adams CM; Baerenwald DA; Zwerner JP; Zic JA; Eischen CM
J Invest Dermatol; 2014 Apr; 134(4):1101-1107. PubMed ID: 24304814
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and Potential Regulatory Role of IL-17F in Pathogenesis of Chronic Periodontitis.
Luo Z; Wang H; Chen J; Kang J; Sun Z; Wu Y
Inflammation; 2015; 38(3):978-86. PubMed ID: 25384562
[TBL] [Abstract][Full Text] [Related]
13. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
[TBL] [Abstract][Full Text] [Related]
14. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
15. A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells.
Fujie H; Niu K; Ohba M; Tomioka Y; Kitazawa H; Nagashima K; Ohrui T; Numasaki M
Inflammation; 2012 Jun; 35(3):1119-31. PubMed ID: 22219048
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation.
Cheung PF; Wong CK; Lam CW
J Immunol; 2008 Apr; 180(8):5625-35. PubMed ID: 18390747
[TBL] [Abstract][Full Text] [Related]
19. Expression of IL-17F is associated with non-pathogenic Th17 cells.
Wanke F; Tang Y; Gronke K; Klebow S; Moos S; Hauptmann J; Shanmugavadivu A; Regen T; Mufazalov IA; Gabriel LA; Reißig S; Diefenbach A; Kurschus FC; Waisman A
J Mol Med (Berl); 2018 Aug; 96(8):819-829. PubMed ID: 29959474
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 Regulates IL-4 Expression in TOX
Huanosta-Murillo E; Alcántara-Hernández M; Hernández-Rico B; Victoria-Acosta G; Miranda-Cruz P; Domínguez-Gómez MA; Jurado-Santacruz F; Patiño-López G; Pérez-Koldenkova V; Palma-Guzmán A; Licona-Limón P; Fuentes-Pananá EM; Lemini-López A; Bonifaz LC
Front Immunol; 2021; 12():668369. PubMed ID: 34220814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
